Curegene
Latest round
- Series C
Last raised
- May 2026
Total raised
- $58M
Investors
- 15
About Curegene
Ltd, trading as Curegene, is a pharmaceutical technology company that provides small molecule and nucleic acid drugs. Gongxin He, the company’s founder and CEO, served as a scientist and senior director of R&D at Gilead Sciences. In 2020, the company completed the construction of its prodrug technology platform. In 2022, it completed CG-0255 preclinical studies and IND filing preparations. The company has built the targeted prodrug and nucleic acid drug technology platform, and is committed to the research and development of small molecules and nucleic acid drugs for the treatment of cardiovascular and cerebrovascular diseases and antiviral. The company's new antiplatelet drug CG-0255 is a P2Y12 receptor antagonist. The drug has completed Phase I clinical trials in the United States, including injection and oral preparations, and can be used for antiplatelet treatment of cardiovascular and cerebrovascular diseases. Curegene has also developed a series of antiviral pipeline products such as CG-0980, CG-0985, and CG2021V, including drugs for children's RSV infection, functional cure of chronic hepatitis B, etc. The company generates revenue by offering drugs in the treatment of cardiovascular and cerebrovascular diseases and antiviral.
Who invested in Curegene
15 investors across 5 rounds
See all investors in Curegene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Curegene
Who invested in Curegene?
Curegene has 15 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Curegene raised?
Curegene has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did Curegene last raise money?
Curegene's most recent round on record is a Series C, in May 2026.
What does Curegene do?
Ltd, trading as Curegene, is a pharmaceutical technology company that provides small molecule and nucleic acid drugs.
Where is Curegene headquartered?
Curegene is headquartered in Shanghai, China.
Which VCs invest in companies like Curegene?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Curegene's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Curegene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.